[go: up one dir, main page]

WO2002078698A3 - Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine - Google Patents

Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine Download PDF

Info

Publication number
WO2002078698A3
WO2002078698A3 PCT/FR2002/001052 FR0201052W WO02078698A3 WO 2002078698 A3 WO2002078698 A3 WO 2002078698A3 FR 0201052 W FR0201052 W FR 0201052W WO 02078698 A3 WO02078698 A3 WO 02078698A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
polarisation
histamine
infections
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/001052
Other languages
French (fr)
Other versions
WO2002078698A2 (en
Inventor
Gerssende Caron
Pascale Jeannin
Jean-Yves Bonnefoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to AU2002255075A priority Critical patent/AU2002255075A1/en
Publication of WO2002078698A2 publication Critical patent/WO2002078698A2/en
Publication of WO2002078698A3 publication Critical patent/WO2002078698A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the use of histamine to induce the polarisation of dendritic cells and, more specifically, to induce the polarisation of dendritic cells into type 2 dendritic cells, which are used, in particular, for the therapeutic and prophylactic treatment of pathologies associated with an excessive Th1 response.
PCT/FR2002/001052 2001-03-29 2002-03-27 Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine Ceased WO2002078698A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002255075A AU2002255075A1 (en) 2001-03-29 2002-03-27 Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104235A FR2822705A1 (en) 2001-03-29 2001-03-29 POLARIZATION OF DENDRITIC CELLS WITH HISTAMINE
FR01/04235 2001-03-29

Publications (2)

Publication Number Publication Date
WO2002078698A2 WO2002078698A2 (en) 2002-10-10
WO2002078698A3 true WO2002078698A3 (en) 2003-05-30

Family

ID=8861681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001052 Ceased WO2002078698A2 (en) 2001-03-29 2002-03-27 Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine

Country Status (3)

Country Link
AU (1) AU2002255075A1 (en)
FR (1) FR2822705A1 (en)
WO (1) WO2002078698A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080395A (en) * 1991-06-14 2000-06-27 Maxim Pharmaceutical, Inc. Method and composition for topical treatment of damaged tissue using histamine as active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080395A (en) * 1991-06-14 2000-06-27 Maxim Pharmaceutical, Inc. Method and composition for topical treatment of damaged tissue using histamine as active ingredient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HELLSTRAND K ET AL: "Role of histamine in natural killer cell-dependent protection against herpes simplex virus type 2 infection in mice", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, (1995 MAY) 2 (3) 277-80., XP001050578 *
LURIE Y (REPRINT) ET AL: "Multicenter, randomized, open-label study of the safety and efficacy of histamine dihydrochloride and interferon alpha-2b for the treatment of chronic hepatitis C: 48-week results", JOURNAL OF HEPATOLOGY, (APR 2001) VOL. 34, SUPP. [1], PP. 165-166. PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS. ISSN: 0168-8278., Kaplan Med Ctr, Rehovot, Israel;Maxim Pharmaceut, San Diego, CA USA, XP001050564 *
VARIOUS: "The Merck manual", 1999, BEERS & BERKOW, N.J., XP002185748 *

Also Published As

Publication number Publication date
FR2822705A1 (en) 2002-10-04
AU2002255075A1 (en) 2002-10-15
WO2002078698A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
PL1641914T3 (en) Postpartum cells derived from placental tissue, and methods of making and using the same
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2006015263A3 (en) Lonidamine analogs
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
UA86345C2 (en) Normal;heading 1;heading 2;USE OF OSTEOPROTEGERIN FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS
WO2000066528A3 (en) Quinones for treatment of diseases
AU2003298911A1 (en) Cyclosporins for the treatment of autoimmune diseases
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
TR200200278T2 (en) Calcilitic compositions
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2002078698A3 (en) Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine
IL154419A0 (en) The treatment of inflammatory disorders
WO2002087612A3 (en) Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases
AU2002348299A1 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2005011728A3 (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
WO2002074330A3 (en) Mycobacterrial estracts for treating autoimmune diseases
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
WO2004075821A3 (en) Cosmetic use of inositol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP